Allegra Freelander

Ms. Allegra Freelander

UNSW Sydney
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CGCristina Guarducci
Cristina Guarducci
ANAgostina Nardone
Agostina Nardone
DRDouglas Russo
Douglas Russo
ZNZsuzsanna Nagy
Zsuzsanna Nagy
CHCapucine Heraud
Capucine Heraud
RJRinath Jeselsohn
Rinath Jeselsohn
Purpose: Resistance to endocrine therapy (ET) and CDK4/6 inhibitors (CDK4/6i) is a clinical challenge in estrogen receptor (ER)-positive (ER+) breast cancer. Cyclin-dependent kinase 7 (CDK7) is a candidate target in endocrine-resistant ER+ breast cancer models and selective CDK7 inhibitors (CDK7i) are in clinical development for the treatment of ER+ breast cancer. Nonetheless, the precise mechanisms responsible for the activity of CDK7i in ER+ breast cancer remain elusive. Herein, we sought to unravel these mechanisms. Experimental Design: We conducted multi-omic analyses in ER+ breast cancer models in vitro and in vivo, including models with different genetic backgrounds. We also performed genome-wide CRISPR/Cas9 knockout screens to identify potential therapeutic vulnerabilities in CDK4/6i-resistant models. Results: We found that the on-target antitumor effects of CDK7 inhibition in ER+ breast cancer are in part p53 dependent, and involve cell cycle inhibition and suppression of c-Myc. Moreover, CDK7 inhibition exhibited cytotoxic effects, distinctive from the cytostatic nature of ET and CDK4/6i. CDK7 inhibition resulted in suppression of ER phosphorylation at S118; however, long-term CDK7 inhibition resulted in increased ER signaling, supporting the combination of ET with a CDK7i. Finally, genome-wide CRISPR/Cas9 knockout screens identified CDK7 and MYC signaling as putative vulnerabilities in CDK4/6i resistance, and CDK7 inhibition effectively inhibited CDK4/6i-resistant models. Conclusions: Taken together, these findings support the clinical investigation of selective CDK7 inhibition combined with ET to overcome treatment resistance in ER+ breast cancer. In addition, our study highlights the potential of increased c-Myc activity and intact p53 as predictors of sensitivity to CDK7i-based treatments.

17 February 2021 in Genes
Verified
Journal Article
Open access
PDF file
AFAllegra Freelander
Allegra Freelander
LBLauren Brown
Lauren Brown
APAndrew Parker
Andrew Parker
DSDavendra Segara
Davendra Segara
NPNeil Portman
Neil Portman
ELElgene Lim
Elgene Lim
Systemic treatment of hormone receptor-positive (HR+) breast cancer is undergoing a renaissance, with a number of targeted therapies including CDK4/6, mTOR, and PI3K inhibitors now approved for use in combination with endocrine therapies. The increased use of targeted therapies has changed the natural history of HR+ breast cancers, with the emergence of new escape mechanisms leading to the inevitable progression of disease in patients with advanced cancers. The identification of new predictive and pharmacodynamic biomarkers to current standard-of-care therapies and discovery of new therapies is an evolving and urgent clinical challenge in this setting. While traditional, routinely measured biomarkers such as estrogen receptors (ERs), progesterone receptors (PRs), and human epidermal growth factor receptor 2 (HER2) still represent the best prognostic and predictive biomarkers for HR+ breast cancer, a significant proportion of patients either do not respond to endocrine therapy or develop endocrine resistant disease. Genomic tests have emerged as a useful adjunct prognostication tool and guide the addition of chemotherapy to endocrine therapy. In the treatment-resistant setting, mutational profiling has been used to identify ESR1, PIK3CA, and AKT mutations as predictive molecular biomarkers to newer therapies. Additionally, pharmacodynamic biomarkers are being increasingly used and considered in the metastatic setting. In this review, we summarise the current state-of-the-art therapies; prognostic, predictive, and pharmacodynamic molecular biomarkers; and how these are impacted by emerging therapies for HR+ breast cancer.

3 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
SKSanjeev Kumar
Sanjeev Kumar
AFAllegra Freelander
Allegra Freelander
ELElgene Lim
Elgene Lim
The nuclear receptor (NR) family of transcription factors is intimately associated with the development, progression and treatment of breast cancer. They are used diagnostically and prognostically, and crosstalk between nuclear receptor pathways and growth factor signalling has been demonstrated in all major subtypes of breast cancer. The majority of breast cancers are driven by estrogen receptor α (ER), and anti-estrogenic therapies remain the backbone of treatment, leading to clinically impactful improvements in patient outcomes. This serves as a blueprint for the development of therapies targeting other nuclear receptors. More recently, pivotal findings into modulating the progesterone (PR) and androgen receptors (AR), with accompanying mechanistic insights into NR crosstalk and interactions with other proliferative pathways, have led to clinical trials in all of the major breast cancer subtypes. A growing body of evidence now supports targeting other Type 1 nuclear receptors such as the glucocorticoid receptor (GR), as well as Type 2 NRs such as the vitamin D receptor (VDR). Here, we reviewed the existing preclinical insights into nuclear receptor activity in breast cancer, with a focus on Type 1 NRs. We also discussed the potential to translate these findings into improving patient outcomes.

1 December 2020 in Current Opinion in Endocrine and Metabolic Research
Verified
Journal Article
Closed access
KCKeeMing Chia
KeeMing Chia
AFAllegra Freelander
Allegra Freelander
SKSanjeev Kumar
Sanjeev Kumar
APAndrew Parker
Andrew Parker
DSDavendra Segara
Davendra Segara
ELElgene Lim
Elgene Lim


1 May 2024
Verified
Other
Open access
PDF file
CGCristina Guarducci
Cristina Guarducci
ANAgostina Nardone
Agostina Nardone
DRDouglas Russo
Douglas Russo
ZNZsuzsanna Nagy
Zsuzsanna Nagy
CHCapucine Heraud
Capucine Heraud
RJRinath Jeselsohn
Rinath Jeselsohn
PalboS and PalboR T47D and MCF7 trancrisptomic and proteomic profile after treatment with SY-1365.